Lower LDL Early and Fight Alzheimer's — Obicetrapib's Dual Promise
Cardiologist Michael Davidson explains how a revived CETP inhibitor lowers LDL, Lp(a), and may protect APOE4 carriers from Alzheimer's.
Summary
In this wide-ranging episode of The Peter Attia Drive, cardiologist and lipidologist Michael Davidson — founding CEO of NewAmsterdam Pharma — makes the case for treating cardiovascular risk early by targeting causal drivers like LDL-C and apoB rather than relying solely on near-term risk scores. The conversation traces the turbulent history of CETP inhibitors, from Pfizer's failed torcetrapib to the resurrection of obicetrapib, which lowers LDL through a distinct mechanism and also reduces Lp(a). Perhaps most provocatively, Davidson discusses emerging evidence that obicetrapib may slow Alzheimer's progression in APOE4 carriers by improving brain cholesterol metabolism through the CETP-APOE4 genetic pathway — with p-tau 217 biomarker data from the BROADWAY trial cited as an early signal.
Detailed Summary
Cardiovascular disease and Alzheimer's disease together account for a vast share of late-life morbidity, yet prevention strategies typically wait until measurable risk thresholds are crossed. Michael Davidson argues this is a fundamental error: because LDL is causally related to atherosclerosis — confirmed by Mendelian randomization — the right metric for intervention is cumulative LDL exposure over a lifetime, not a 10-year risk score.
The episode recounts the graveyard of CETP inhibitors: Pfizer's torcetrapib raised HDL dramatically but increased blood pressure and mortality; Roche's dalcetrapib, Lilly's evacetrapib, and Merck's REVEAL trial followed with mixed or null outcomes. Davidson explains why obicetrapib differs — its LDL-lowering effect, not HDL raising, appears to be the active mechanism, validated by Mendelian randomization showing HDL is not causally protective on its own.
Obicetrapib's clinical program includes Phase 2 and 3 trials (ROSE, BROOKLYN, BROADWAY, TANDEM) and the ongoing PREVAIL outcomes trial, with European and US approval paths in progress. The drug lowers LDL-C, reduces apoB, and meaningfully cuts Lp(a) — a lipoprotein increasingly recognized as an independent cardiovascular risk factor. The episode also examines discordance between LDL-C, LDL particle number, and apoB when CETP is inhibited.
The most forward-looking section explores obicetrapib's potential in Alzheimer's disease. APOE4 disrupts astrocyte cholesterol efflux across the blood-brain barrier, promoting amyloid and tau pathology. CETP genetics overlap with APOE4 biology, and animal models support a brain-protective effect. Davidson discusses p-tau 217 biomarker results from the BROADWAY trial — a validated Alzheimer's marker — as an early signal supporting further investigation, motivating a potential prevention trial in APOE4 carriers.
Caveats are substantial: outcomes data from PREVAIL are pending, the Alzheimer's evidence is limited to biomarker-level signals, and the amyloid hypothesis remains contested. Nonetheless, the convergence of cardiovascular and neurological benefit in a single oral agent represents a compelling longevity hypothesis deserving rigorous follow-up.
Key Findings
- LDL is causally linked to atherosclerosis; lifetime cumulative exposure — not 10-year risk — should guide when to start lipid-lowering therapy.
- Obicetrapib lowers LDL-C, apoB, and Lp(a) through CETP inhibition, with LDL reduction — not HDL raising — driving cardiovascular benefit.
- The BROADWAY trial produced p-tau 217 biomarker results (a validated Alzheimer's marker) that Davidson highlights as an early signal warranting follow-up.
- APOE4 impairs brain cholesterol metabolism via astrocyte efflux pathways; CETP inhibition may partially restore this function.
- High-dose statins carry a measurable diabetes signal; a lower-dose statin plus obicetrapib may offer equivalent LDL lowering with less metabolic risk.
Methodology
This is a long-form expert interview, not a primary study. Clinical evidence cited includes Phase 2–3 randomized trials (ROSE, BROOKLYN, BROADWAY, TANDEM), the ongoing PREVAIL cardiovascular outcomes trial, Mendelian randomization analyses on LDL and HDL causality, and a CSF pilot biomarker study for Alzheimer's. The p-tau 217 finding from BROADWAY is presented as an exploratory signal, not a pre-specified primary endpoint.
Study Limitations
This summary is based on a podcast episode transcript and chapter descriptions rather than a peer-reviewed publication; no primary data were independently verified. The Alzheimer's benefit is supported only by biomarker signals (p-tau 217) from a trial powered for cardiovascular endpoints — clinical outcomes in cognition remain unproven. PREVAIL outcomes data are pending, and regulatory approval in the US has not yet been granted.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: